reading cagrilintide threads from 2024 and half of it aged badly
reading cagrilintide threads from 2024 and half of it aged badly. Not a hot take, just something I have not seen said plainly here.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
Tell me where this is wrong. That is the useful part of posting it.
best — the order this archive was captured in
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.
[removed by moderator]
Are you comparing against a GLP-1 monotherapy result? They are not comparable.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Do you have the publication or a summary of it?
Are you comparing against a GLP-1 monotherapy result?
Agreed, and the combination arms are where the interesting numbers actually live.
amylin analogue, different receptor family, different story
read the combination arms separately from the monotherapy arms
amylin analogue, different receptor family, different story
Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.
Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
Standing reminder: nothing here is approved standalone, research material is not for human use, and no dosing schedules for other members.
do not assume the dosing intuitions from the GLP-1 boards transfer
This. Complementary mechanisms rather than more of the same is the actual argument for the pairing.
This.
amara_kuipers is right that the evidence base here is thin. Conclusions should be held loosely.
Sent a vial to VendorInvestigate because there was almost nothing on file for this compound. 99.6% against a claimed 99.0%, and I posted it because the log needs entries.
- 1Dosing intuitions from the GLP-1 boards do not transfer. Different receptor…11 comments in this branch · started by u/pancreatitis_scare